胸腺肽α1治疗肠结核的近期疗效观察

Short-term Efficacy of thymosin α1 in the treatment of intestinal tuberculosis

目的:观察胸腺肽α1对肠结核患者的近期疗效和安全性。方法:选择96例肠结核患者,随机分为对照组和试验组。对照组给予常规抗结核治疗,试验组在此基础上加用胸腺肽α1治疗,在治疗前和治疗16周后检测患者外周血T细胞亚群及NK细胞的水平。结果:对照组患者治疗前后差异无显著性,试验组治疗后CD3+、CD4+、CD4+/CD8+较治疗前显著增高,且试验组临床疗效更好。结论:常规抗结核治疗联用胸腺肽α1能够显著改善肠结核患者的机体免疫功能状态,有效提高临床疗效,且安全性良好。

Objective To observe the short-term efficacy and safety of thymosin α1 in the treatment of in-testinal tuberculosis. Methods 96 intestinal tuberculosis patients were enrolled in the study and were randomly di-vided into 2 groups. Control group received conventional anti-TB treatment; trial group received additional thy-mosin α1. Data were collected between the two groups before and after 16 weeks' treatment, including the fre-quencies of peripheral blood T-lymphocyte subsets and NK cells. Results There was no significant difference in the control group before and after treatment. After 16 weeks' treatment, the values of CD3+, CD4+ and CD4+/CD8+in trial group was significantly higher than that before treatment, and the clinical efficacy of trail group was better than control group. Conclusion Thymosin α1 combined with conventional anti-TB treatment could signifi-cantly improve the intestinal immunologic function, and enhance the short-term efficacy in intestinal tuberculosis patients with good safety.